Drugs / PEGLOPRASTIDE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02391194 | Apr 2015 → Jan 2017 | breast cancer | Avelas Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03113825 | Jul 2017 → Apr 2020 | breast ductal adenocarcinoma, female breast carcinoma, invasive breast carcinoma | Avelas Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGLOPRASTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095310 ↗ |
| Known as | AVB-620 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03113825 ↗ |
| Modality | Diagnostic / imaging agent | “generate a fluorescence signal in tumor and lymph node tissue to enable fluorescence recordings and image analysis with an imaging system” NCT02391194 ↗ |
| Route | Intravenous | “AVB-620 administered as an IV infusion” NCT02391194 ↗ |